Efficacy exploration of 2nd line in advanced colorectal cancer

Interventions: Drug : Registry study
Day 1. Aflibercept + FOLFIRI
• aflibercept(Zaltrap): 4 mg/kg IV infusion for over 1hr (Do not administer as an IV push or bolus)
• Leucovorin: 400 mg/m2 IV infusion for over 2 hours
• Irinotecan: 150 mg/m2 IV infusion for over 1 hours
• 5-FU: 400 mg/m2 IV bolus injection for over 5 minute
• 5-FU: 2400 mg/m2IV continuous infusion for 46 hours
every 2 weeks until progression disease or death or unacceptable toxicity
17 potential protein biomarkers, including cytokines and angiogenic factors, is chosen for analysis based on their roles in tumor progression: HGF, PIGF, VEGF-A, VEGF-C, VEGF-D, INF-r, IL-6, IL-8, Angiopoietin-2, sNeuropillin-1, TSP-2, OPN, sVEGFR1,2,3, sICAM-1, sVCAM-1, and TIMP-1
- Plasma is collected at baseline (Cycle 1) and cycle 4
- Plasma levels of the potential biomarkers are determined by enzyme-linked immunosorbent assays
Primary outcome(s): Profression free survival